Reimbursement issues in clinical oncology.
In this multidisciplinary review, health-care specialists present practical solutions to the dilemma of rising costs v the need for adequate medical care for all Americans. The United States is the only advanced industrial society that makes ability to pay a critical determinant in health care. As the costs of patient care and insurance coverage escalate, the public demands greater value in insurance coverage with enhanced access to adequate care, clinical trials, and experimental therapies. Greater cooperation is needed between third-party payers, business, and government to create a system that provides optimal care today while supporting innovation and emerging technology for the future.
Vogelzang
N J
NJ
University of Chicago, Joint Section of Hematology/Oncology, IL 60637.
Chabner
B A
BA
Periman
P
P
Ohrt
D K
DK
McCann
B C
BC
Burns
J M
JM
Bayer
R
R
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002173:Cancer Care Facilities; D002986:Clinical Trials as Topic; D003363:Cost Control; D003365:Costs and Cost Analysis; D006801:Humans; D007349:Insurance, Health, Reimbursement; D008489:Medical Indigency; D006278:Medicare; D009369:Neoplasms / Q000191:economics* / Q000628:therapy; D012935:Social Justice; D014481:United States
D000970:Antineoplastic Agents